Answers are grounded in this paper and cite their sources.
Metastatic liver disease is one of the major causes of cancer-related morbidity and mortality. Locoregional therapies offered by interventional oncologists alleviate cancer-related morbidity and in some cases improve survival. Locoregional therapies are often palliative in nature but occasionally can be used with curative intent. This review will discuss important factors to consider prior to palliative and curative intent treatment of metastatic liver disease with locoregional therapy. These factors include those specific to the tumor, liver function, liver reserve, differences between treatment modalities, and patient-specific considerations.
No takes yet. Share an insight, caveat, or question.
O’Leary et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: